Cancer Network interviews two prominent ovarian cancer researchers from both sides of the Atlantic on the role of PARP inhibitors and the challenges of developing ovarian cancer therapies.
Michael Birrer, MD, PhD
Advertisement
Articles by Michael Birrer, MD, PhD
Advertisement
Latest Updated Articles
PARP Inhibitors and the Challenges of Developing Ovarian Cancer TherapeuticsPublished: March 7th 2012 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Regorafenib/Nivolumab Exhibits Nonsuperior Survival in Gastric Cancer
2
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
3
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
4
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
5
